---
figid: PMC6695603__ijms-20-03821-g004
figtitle: Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein
  (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell
  Lung Cancer (NSCLC)
organisms:
- NA
pmcid: PMC6695603
filename: ijms-20-03821-g004.jpg
figlink: /pmc/articles/PMC6695603/figure/ijms-20-03821-f004/
number: F4
caption: In EGFR mutant NSCLC without targetable resistant mutations, activation of
  YAP enhances the downstream genes expression of EGFs, ERBB3, ERBB4, CTGF, and CYR61
  to form an autocrine loop and reinforce MAPK signaling pathway to induce cancer
  progression, drugs resistance, and immune escape. YAP blockade by MEK 1/2, CDK1,
  CDK9, and YAP-TEAD complex inhibitors in combination with anti-PD-1/PD-L1 ICIs may
  be a future therapeutic strategy for the treatment of EGFR mutant NSCLC without
  targetable resistant mutations.
papertitle: Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein
  (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell
  Lung Cancer (NSCLC).
reftext: Ping-Chih Hsu, et al. Int J Mol Sci. 2019 Aug;20(15):3821.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9611997
figid_alias: PMC6695603__F4
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC6695603__F4
ndex: 90796b20-ded8-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6695603__ijms-20-03821-g004.html
  '@type': Dataset
  description: In EGFR mutant NSCLC without targetable resistant mutations, activation
    of YAP enhances the downstream genes expression of EGFs, ERBB3, ERBB4, CTGF, and
    CYR61 to form an autocrine loop and reinforce MAPK signaling pathway to induce
    cancer progression, drugs resistance, and immune escape. YAP blockade by MEK 1/2,
    CDK1, CDK9, and YAP-TEAD complex inhibitors in combination with anti-PD-1/PD-L1
    ICIs may be a future therapeutic strategy for the treatment of EGFR mutant NSCLC
    without targetable resistant mutations.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGF
  - EGFR
  - ERBB3
  - ERBB4
  - CCN2
  - CCN1
  - KRAS
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - CD274
  - EPHB2
  - YAP1
  - CDK9
  - CDK1
  - TEAD1
  - TEAD2
  - TEAD3
  - TEAD4
  - AREG
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - VSIR
  - H
  - NSCLC
  - PD-LI
  - metastasis
---
